Phaseline

Targets › GUCY1A1

GUCY1A1 (Guanylate cyclase soluble subunit alpha-1): drug programs, companies and trials

15 programs from 14 companies in 29 trials: 13 Phase 2, 7 Phase 4, 6 Phase 3, 3 Phase 1; Cardiovascular, Oncology, Genitourinary; next expected readout Dec 2026.

Alpha subunit of soluble guanylate cyclase (sGC), a key enzyme in nitric oxide (NO) signaling. sGC functions as a heterodimer consisting of one alpha and one beta subunit. It serves as the primary intracellular receptor for NO, which binds to a heme prosthetic group located on the beta subunit. (UniProt, Q02108)

Open in Phaseline: the race on GUCY1A1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Copenhagen University Hospital, RigshospitaletIsosorbide Dinitrate
Nitrate; nitric oxide donor causing vasodilation
GUCY1A1, GUCY1B1Phase 4Pulmonary EdemaMay 2027
National Cheng-Kung University HospitalNitroglycerin
Soluble guanylate cyclase activator
GUCY1B1, GUCY1A2, GUCY1A1Phase 4PancreatitisJul 2027
Pulmovantinhaled mosliciguat
soluble guanylate cyclase stimulator
GUCY1A1, GUCY1B1Phase 3Pulmonary HypertensionDec 2026
Children's Hospital Medical Center, CincinnatiNitric Oxide
Soluble guanylate cyclase activator
GUCY1B1, GUCY1A2, GUCY1A1Phase 3AKIJun 2027
Xijing HospitalNitric Oxide
Soluble guanylate cyclase activator
GUCY1B1, GUCY1A2, GUCY1A1Phase 3Nitric OxideMar 2028
BayerRiociguat
Soluble guanylate cyclase positive allosteric modulator
GUCY1B1, GUCY1A2, GUCY1A1Phase 3Hypertension, Pulmonary; Chronic Thromboembolic Pulmonary Hypertension; Pulmonary Arterial HypertensionMay 2028
Akebia TherapeuticsPraliciguat
Soluble guanylate cyclase activator
GUCY1B1, GUCY1A2, GUCY1A1Phase 2Focal Segmental GlomerulosclerosisJun 2027
Coherus OncologyCasdozokitug
Soluble guanylate cyclase stimulator
GUCY1A1, GUCY1B1Phase 2Hepatocellular CarcinomaSep 2027
KardiganAtaciguat
Soluble guanylate cyclase activator
GUCY1B1, GUCY1A2, GUCY1A1Phase 2Moderate Aortic Valve StenosisAug 2028
Merck & Co. (MSD)Vericiguat
Soluble guanylate cyclase activator
GUCY1B1, GUCY1A2, GUCY1A1Phase 2Heart Failure; Heart Failure With Reduced Ejection Fraction (HFrEF); Endothelial Dysfunction; Post-COVID ME/CFS …Aug 2029
Merck & Co. (MSD)Frespaciguat (MK-5475)
Soluble guanylate cyclase (sGC) stimulator
GUCY1A1, GUCY1B1Phase 2Pulmonary HypertensionOct 2029
Steven MesseNitric Oxide
Soluble guanylate cyclase activator
GUCY1B1, GUCY1A2, GUCY1A1Phase 2Stroke–
Beni-Suef UniversityNitroglycerin
Soluble guanylate cyclase activator
GUCY1B1, GUCY1A2, GUCY1A1Phase 2COPD–
Mayo ClinicIsosorbide Mononitrate
Soluble guanylate cyclase activator
GUCY1B1, GUCY1A2, GUCY1A1Phase 1Malignant Digestive System NeoplasmApr 2028
Vanderbilt UniversityNitroglycerin
Soluble guanylate cyclase activator
GUCY1B1, GUCY1A2, GUCY1A1Phase 1HypertensionJul 2028

Conditions

Pulmonary Hypertension (4) Heart Failure (3) Chronic Thromboembolic Pulmonary Hypertension (2) Pulmonary Arterial Hypertension (2) Nitric Oxide (1) COPD (1) Heart Failure With Reduced Ejection Fraction (HFrEF) (1) Endothelial Dysfunction (1) Post-COVID ME/CFS (1) Breast Cancer (1) Calcific Aortic Valve Disease (1) Decompensated Heart Failure (1)

Modalities

small molecule (14), antibody (1)

Companies

Merck & Co. (MSD) (2) Pulmovant (1) Xijing Hospital (1) Beni-Suef University (1) National Cheng-Kung University Hospital (1) Children's Hospital Medical Center, Cincinnati (1) Kardigan (1) Coherus Oncology (1) Bayer (1) Akebia Therapeutics (1) Vanderbilt University (1) Mayo Clinic (1) Steven Messe (1) Copenhagen University Hospital, Rigshospitalet (1)

Related targets

GUCY1B1 (15) GUCY1A2 (11)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.